ArticleHeart and vessels2025
Heart-rate reduction during microaxial flow pump support and short-term outcomes in patients with cardiogenic shock.
Article in Heart and vessels, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Simple risk stratification of patients with ST-segment elevation myocardial infarction: based on the modified DanGer shock trial-derived criteria assessed at initial emergency room presentation.Heart and vessels · 2026Article
- Optimal surgical management of patients with severely reduced left ventricular ejection fraction undergoing coronary artery bypass grafting.Heart and vessels · 2026Article
- UNLOADERS-PVAD Weaning Score: predicting post-weaning adverse events in cardiogenic shock patients supported by microaxial flow pump.Journal of intensive care · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart rate (HR) is a surrogate of systemic conditions, cardiac performances, and effect of chronotropic agents in patients with critical illness. The current study aimed to elucidate the association between HR during mechanical circulatory support with the Impella microaxial flow pump and clinical outcomes in patients with cardiogenic shock (CS). This study evaluated 92 patients (mean age: 67 ± 13 years; male: 77%) with CS who received temporary circulatory support with Impella. The absolute HR immediately before Impella implantation, at 24 h after implantation, immediately before explantation, and at 24 h after explantation, and its association with short-term outcomes were assessed. In total, 47 (51%) patients concomitantly used venoarterial extracorporeal membrane oxygenation. Patients who died or those who were bridged to left ventricular assist device (LVAD) implantation during Impella support (n = 20) were excluded from the outcome analysis. Four patients died within 24 h after Impella initiation. During Impella support, 14 patients died, and two had LVAD implantation. A high HR and a higher lactate level at Impella explantation were independently associated with 30 day mortality in 18 (25%) patients. An HR of < 82 bpm at Impella explantation was the optimal cutoff value for indicating a lower incidence of 30 day mortality. Up-titrated beta-blockers and decreases in the vasoactive-inotropic score were correlated with HR reduction during Impella support. In patients with CS receiving Impella support, a lower HR at weaning was associated with a decreased incidence of short-term mortality. HR reduction was a simple prognostic indicator, and chronotropic interventions including beta-blockers may be therapeutic options for patients with CS receiving Impella support.
Indexed as
Identifiers
40047891What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.